According to Pharm Exec Senior Editor Ben Comer, the biosimilars that were supposed to save consumers and taxpayers money as “the first wave of biologics” went off patent are unlike generic drugs because they take so long to develop and involve costly manufacturing and clinical trials—some seven to eight years in development with costs of up to $250 million. He suggests that with the biosimilars market expected “to climb to nearly $20 billion by 2018, it seems unlikely that health systems, in the U.S. and elsewhere, will see a dramatic decline in the overall cost of prescrip- tion drugs due to biosimilars.” See, January 21, 2014.